SOPHIA GENETICS SA (SOPH) Stock Fundamental Analysis
USA - NASDAQ:SOPH - CH1125843347 - Common Stock
4.09 USD
-0.11 (-2.62%)
We assign a fundamental rating of 2 out of 10 to SOPH. SOPH was compared to 35 industry peers in the Health Care Technology industry. SOPH may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, SOPH is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year SOPH has reported negative net income.
In the past year SOPH has reported a negative cash flow from operations.
SOPH had negative earnings in each of the past 5 years.
SOPH had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
SOPH's Return On Assets of -45.10% is on the low side compared to the rest of the industry. SOPH is outperformed by 71.43% of its industry peers.
SOPH has a worse Return On Equity (-77.29%) than 68.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -45.1% | ||
| ROE | -77.29% | ||
| ROIC | N/A |
ROA(3y)-38.14%
ROA(5y)-33.44%
ROE(3y)-53.54%
ROE(5y)-45.3%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 68.09%, SOPH is in the better half of the industry, outperforming 68.57% of the companies in the same industry.
In the last couple of years the Gross Margin of SOPH has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for SOPH so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.09% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.64%
GM growth 5Y-0.84%
2. Health
2.1 Basic Checks
SOPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SOPH has been increased compared to 1 year ago.
SOPH has more shares outstanding than it did 5 years ago.
SOPH has a worse debt/assets ratio than last year.
2.2 Solvency
SOPH has an Altman-Z score of -1.41. This is a bad value and indicates that SOPH is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.41, SOPH is doing worse than 65.71% of the companies in the same industry.
SOPH has a Debt/Equity ratio of 0.33. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.33, SOPH perfoms like the industry average, outperforming 42.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.33 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.41 |
ROIC/WACCN/A
WACC5.01%
2.3 Liquidity
SOPH has a Current Ratio of 3.11. This indicates that SOPH is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 3.11, SOPH is doing good in the industry, outperforming 65.71% of the companies in the same industry.
A Quick Ratio of 2.94 indicates that SOPH has no problem at all paying its short term obligations.
SOPH has a Quick ratio of 2.94. This is in the better half of the industry: SOPH outperforms 68.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.11 | ||
| Quick Ratio | 2.94 |
3. Growth
3.1 Past
The earnings per share for SOPH have decreased by -7.84% in the last year.
SOPH shows a small growth in Revenue. In the last year, the Revenue has grown by 7.31%.
Measured over the past years, SOPH shows a very strong growth in Revenue. The Revenue has been growing by 20.78% on average per year.
EPS 1Y (TTM)-7.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-43.48%
Revenue 1Y (TTM)7.31%
Revenue growth 3Y17.23%
Revenue growth 5Y20.78%
Sales Q2Q%15.91%
3.2 Future
SOPH is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.68% yearly.
SOPH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.45% yearly.
EPS Next Y-15.69%
EPS Next 2Y3.89%
EPS Next 3Y10.68%
EPS Next 5YN/A
Revenue Next Year14.34%
Revenue Next 2Y16.69%
Revenue Next 3Y18.63%
Revenue Next 5Y20.45%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SOPH. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SOPH. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.89%
EPS Next 3Y10.68%
5. Dividend
5.1 Amount
No dividends for SOPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:SOPH (10/28/2025, 4:30:02 PM)
4.09
-0.11 (-2.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners37.8%
Inst Owner Change0%
Ins Owners6.46%
Ins Owner ChangeN/A
Market Cap276.40M
Revenue(TTM)69.69M
Net Income(TTM)-66174000
Analysts86
Price Target7.14 (74.57%)
Short Float %0.03%
Short Ratio0.27
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.83%
Min EPS beat(2)-2.99%
Max EPS beat(2)-0.67%
EPS beat(4)1
Avg EPS beat(4)-0.71%
Min EPS beat(4)-19.35%
Max EPS beat(4)20.18%
EPS beat(8)3
Avg EPS beat(8)2.28%
EPS beat(12)7
Avg EPS beat(12)8.94%
EPS beat(16)10
Avg EPS beat(16)10.55%
Revenue beat(2)1
Avg Revenue beat(2)0.55%
Min Revenue beat(2)-1.89%
Max Revenue beat(2)2.98%
Revenue beat(4)1
Avg Revenue beat(4)-2.94%
Min Revenue beat(4)-10.93%
Max Revenue beat(4)2.98%
Revenue beat(8)2
Avg Revenue beat(8)-2.64%
Revenue beat(12)3
Avg Revenue beat(12)-2.12%
Revenue beat(16)5
Avg Revenue beat(16)-0.8%
PT rev (1m)0%
PT rev (3m)-8.7%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-17.12%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.4%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 4.11 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.23 | ||
| P/tB | 4.97 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.1
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.7
FCFYN/A
OCF(TTM)-0.59
OCFYN/A
SpS0.99
BVpS1.27
TBVpS0.82
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -45.1% | ||
| ROE | -77.29% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.09% | ||
| FCFM | N/A |
ROA(3y)-38.14%
ROA(5y)-33.44%
ROE(3y)-53.54%
ROE(5y)-45.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.64%
GM growth 5Y-0.84%
F-Score3
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.33 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 87.27% | ||
| Cap/Sales | 11.48% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.11 | ||
| Quick Ratio | 2.94 | ||
| Altman-Z | -1.41 |
F-Score3
WACC5.01%
ROIC/WACCN/A
Cap/Depr(3y)130.72%
Cap/Depr(5y)142.16%
Cap/Sales(3y)16.39%
Cap/Sales(5y)15.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-43.48%
EPS Next Y-15.69%
EPS Next 2Y3.89%
EPS Next 3Y10.68%
EPS Next 5YN/A
Revenue 1Y (TTM)7.31%
Revenue growth 3Y17.23%
Revenue growth 5Y20.78%
Sales Q2Q%15.91%
Revenue Next Year14.34%
Revenue Next 2Y16.69%
Revenue Next 3Y18.63%
Revenue Next 5Y20.45%
EBIT growth 1Y14.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year38.2%
EBIT Next 3Y22.4%
EBIT Next 5Y23.92%
FCF growth 1Y38.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.12%
OCF growth 3YN/A
OCF growth 5YN/A
SOPHIA GENETICS SA / SOPH FAQ
What is the fundamental rating for SOPH stock?
ChartMill assigns a fundamental rating of 2 / 10 to SOPH.
What is the valuation status of SOPHIA GENETICS SA (SOPH) stock?
ChartMill assigns a valuation rating of 0 / 10 to SOPHIA GENETICS SA (SOPH). This can be considered as Overvalued.
How profitable is SOPHIA GENETICS SA (SOPH) stock?
SOPHIA GENETICS SA (SOPH) has a profitability rating of 1 / 10.